Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 32, Number 2—February 2026
Research Letter
Monkeypox Virus Antibodies in Healthy Persons after Vaccination with MVA-BN, United Kingdom
Victoria H. Sheridan, Craig W. Duffy, Jake Dunning, Lance Turtle, Julian A. Hiscox, Krishanthi S. Subramaniam
, and on behalf of the ISARIC4C Investigators1
, and on behalf of the ISARIC4C Investigators1
Table
Demographics of the participant cohort in study of monkeypox virus antibodies in healthy persons after MVA-BN vaccination, United Kingdom*
| Characteristic | MVA-BN vaccine recipients, N = 25 |
|---|---|
| Median age, y (IQR) |
39 (30–45) |
| Sex, no. (%) | |
| M | 9 (36) |
| F |
16 (64) |
| Ethnicity, no. (%) | |
| White | 20 (80) |
| Asian | 3 (12) |
| Latin |
2 (8) |
| Underlying conditions, no. | |
| Multiple sclerosis | 1 |
| Psoriasis | 1 |
| Asthma | 1 |
*IQR, interquartile range; MVA-BN, modified vaccinia Ankara–Bavarian Nordic.
1More information about the group is at the end of this article.
Page created: January 22, 2026
Page updated: February 15, 2026
Page reviewed: February 15, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.